World Bank bars Famy Care, Olive Healthcare from receiving its contracts
Teena Thacker, Aug 4, 2017 Two India-based pharmaceutical companies have been barred from receiving World Bank contracts after an investigation revealed that they had engaged in “fraud” and “misconduct”, the multilateral lender said. Mumbai-based contraceptive drugmaker Famy Care Ltd and Olive Healthcare, a pharmaceutical company that manufacturers dietary supplements in soft gelatin dosage forms, were banned from participating in World Bank-financed projects for “violating procurement guidelines” The announcement was made by the World Bank’s Sanctions Board following investigations by integrity vice presidency (INT), which is responsible for investigating corruption in World Bank-financed projects. Famy Care and Olive Healthcare did not respond to emails sent by Mint seeking comments. Mumbai-based Olive Health Care was disqualified until January 2028 from participation in World Bank-financed projects. INT claimed that the company “knowingly engaged in fraudulent pra...